Recent news on Enfuvirtide

Elimination of HIV from body within 8 years if treatment starts ...  -  May 17, 2007
Aidsmap,They also plan to use Merck's new integrase inhibitor raltegravir (Isentress) and the Roche fusion inhibitor enfuvirtide (Fuzeon) in future patients,

New option for highly pretreated patients with HIV  -  Apr 26, 2007
Healthcare Republic...reverse transcriptase inhibitors with optional enfuvirtide) and one of four doses of darunavir (with ritonavir) or other control protease inhibitors. 1

New option for highly pretreated patients with HIV  -  26 Apr 2007
Healthcare Republic...reverse transcriptase inhibitors with optional enfuvirtide) and one of four doses of darunavir (with ritonavir) or other control protease inhibitors. 1

Discovery of an HIV inhibitor in human blood points to new type of ...  -  Apr 19, 2007
Aidsmap,The modified forms were equally active against all drug-resistant viruses tested, including those showing resistance to enfuvirtide.

Peptide Found in Human Blood Inhibits 60 Strains of HIV, Study Says  -  Apr 20, 2007
MedIndia,He added that the peptide might work synergistically with the antiretroviral drug Fuzeon, which also is known as enfuvirtide or T-20 and was approved by FDA

Darunavir looking promising as companion for agents in new HIV ...  -  Apr 4, 2007
Aidsmap,In the POWER 1 & 2 studies individuals who had no prior exposure to the fusion inhibitor enfuvirtide (Fuzeon), and who included the drug in their optimised

Survey Finds Medicare Part D Failing People with HIV/AIDS  -  Apr 6, 2007
Kansas City infoZine,...the Centers for Medicare and Medicaid Services (CMS) specifically exempts all but one antiretroviral, enfuvirtide (Fuzeon), from prior authorization.

Darunavir Effective in Resistant HIV  -  Apr 5, 2007
MedPage Today,On the basis of a logistic regression model including stratification factors (baseline number of primary protease inhibitor mutations, use of enfuvirtide,

Narrative Review: Antiretroviral Therapy to Prevent the Sexual ...  -  Apr 16, 2007
Annals of Internal MedicinePenetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS. 2004;18:1958-61.

FDA updates product labelling for T-20 after Biojector found to ...  -  Feb 5, 2007
Aidsmap,Use of Biojector 2000, a needle-free device to administer the anti-HIV drug T-20 (enfuvirtide, Fuzeon), has caused long-lasting nerve pain, bruising and

European Approval Of HIV Drug Darunavir Will Provide A Potent New ...  -  Feb 21, 2007
Medical News Today (press release),Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus

Mixed HIV coreceptor use associated with lower CD4 count than ...  -  Feb 1, 2007
Aidsmap,In an accompanying commentary, Thomas Melby of Trimeris, the company which developed the HIV entry inhibitor enfuvirtide (Fuzeon) concurs, noting a trend

J&J unit's HIV drug Prezista gets conditional OK in Europe  -  Feb 19, 2007
Pharma Times (subscription),...by Roche which said that it "provides physicians with the opportunity to build a potent new treatment combination" with the firm's Fuzeon (enfuvirtide).

Exploiting natural HIV defence  -  Feb 9, 2007
BiopharmaReporter.com,The first fusion inhibitor was Roche's Fuzeon (enfuvirtide), approved in 2003. It is, however, costly to prescribe and because of this, it is generally

FDA Announces Important Changes to Fuzeon Product Labeling  -  Feb 1, 2007
PharmaLive.com (press release),31, 2007--Important additions have been made to the Fuzeon (enfuvirtide) for injection product label to include a description of nerve bundle pain,

Roche Posts Outstanding Results for 2006  -  Feb 7, 2007
PharmaLive.com (press release),Sales of Fuzeon (enfuvirtide), which works by blocking the entry of HIV into cells of the immune system, rose 19% compared with 2005.

Antiretroviral Therapy for HIV: New Data From HIV 8 in Glasgow  -  Dec 26, 2006
Medscape (subscription)Darunavir performed much better than either enfuvirtide or tipranavir/r. [18] In light of these results, the estimated potency, barrier to drug resistance,

Mumbai pharmacies putting AIDS patients at risk  -  Dec 20, 2006
Times of India,In a shocking revelation, UNAIDS officials have found that private pharmacies in Mumbai are openly selling third line ART called Enfuvirtide.

After 48 weeks of study, and 24 weeks in the real world, darunavir ...  -  Dec 21, 2006
Aidsmap,...any other approved ritonavir-boosted PI along with an optimised background regimen – which included two or more NRTIs and/or enfuvirtide (T-20, Fuzeon).

Strategies for coping with multiple drug resistance  -  Dec 20, 2006
NAPWA,The fusion inhibitor T-20 (enfuvirtide, Fuzeon) is one option that should be considered. T-20 is available on the PBS and has proven a powerful tool,

Antiretroviral Therapy for HIV: New Data From HIV 8 in Glasgow  -  26 Dec 2006
Medscape (subscription)Darunavir performed much better than either enfuvirtide or tipranavir/r. [18] In light of these results, the estimated potency, barrier to drug resistance,

After 48 weeks of study, and 24 weeks in the real world, darunavir ...  -  Dec 21, 2006
Aidsmap,...any other approved ritonavir-boosted PI along with an optimised background regimen – which included two or more NRTIs and/or enfuvirtide (T-20, Fuzeon).

Mumbai pharmacies putting AIDS patients at risk  -  Dec 20, 2006
Times of India,In a shocking revelation, UNAIDS officials have found that private pharmacies in Mumbai are openly selling third line ART called Enfuvirtide.

Strategies for coping with multiple drug resistance  -  Dec 20, 2006
NAPWA,The fusion inhibitor T-20 (enfuvirtide, Fuzeon) is one option that should be considered. T-20 is available on the PBS and has proven a powerful tool,

Committee for Medicinal Products for Human Use Summary of Positive ...  -  Dec 15, 2006
PharmaLive.com (press release),...nucleoside reverse transcriptase inhibitors (NRTIs) and with or without the fusion inhibitor enfuvirtide, chosen on the basis of HIV resistance testing.

Why did HIV therapy have some benefits for a man with resistance ...  -  Dec 12, 2006
Aidsmap,...resistance to all the available antiretroviral drugs except 3TC (lamivudine, Epivir), FTC (emtricitabine, Emtriva) and T-20 (enfuvirtide, Fuzeon).

Pfizer announces expanded access programme for maraviroc  -  Nov 30, 2006
Aidsmap,When it becomes available maraviroc is likely to be the first agent of a new drug class to be approved since enfuvirtide (T-20, Fuzeon), but is likely to be

ICAAC 2006 - The Anti-HIV Drug Pipeline CME  Nov 6, 2006
Finally, there was important information on the sole currently approved fusion inhibitor, enfuvirtide (T-20), and hope for a next-generation member of the ... -Medscape (subscription) Antiretroviral Drug Resistance in Patients With HIV  Nov 6, 2006
...a better understanding of the role of gp41 in influencing tropism and whether this role is influenced (either positively or negatively) by enfuvirtide treatment ... -Medscape (subscription) Antiretroviral Treatment Strategies for Adults With HIV  Nov 2, 2006
...studies that randomized triple-class-experienced patients to receive investigator-selected optimized background of NRTIs with or without enfuvirtide (ENF) with ... -Medscape (subscription) New drug to be funded for HIV/Aids sufferers  Oct 31, 2006
Pharmac began subsidising enfuvirtide, the first of a new class of anti-HIV drugs, which block HIV virus from entering the body's cells, in September. -Stuff.co.nz, Aptivus®(tipranavir) Demonstrates Durable Response Through Nearly ...  Oct 15, 2006
Aptivus, and this increased to 369.5 days for those who received Aptivus® with a new active antiretroviral agent in the background regimen, such as enfuvirtide ... -Medical News Today (press release), HIV treatment takes two steps forward  Oct 31, 2006
Atazanavir will join five other fully subsidised HIV protease inhibitors. Another treatment for HIV/AIDS, enfuvirtide, has also been funded recently. -Scoop.co.nz (press release), FUZEON Combined With New Investigational HIV Drug Results in ...  Oct 9, 2006
Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON(R) (enfuvirtide) and the ... -Drug Newswire (press release), Roche, Trimeris Announce Study Results Indicating Fuzeon, MK-0518 ...  Oct 10, 2006
Roche and biopharmaceutical company Trimeris on Thursday announced that their antiretroviral drug Fuzeon -- known generically as enfuvirtide -- in combination ... -Kaiser network.org, Darunavir response did not differ by prior PI in POWER studies  Oct 8, 2006
...twice daily. The new combinations may or may not also have included enfuvirtide (T-20, Fuzeon); none contained any NNRTIs. The study ... -Aidsmap, Roche and Trimeris Provide Update on Development of Needle-Free ...  Oct 11, 2006
...today provided an update on the companies' development plans for administration of FUZEON(R) (enfuvirtide) with a needle-free injection device (Biojector(R ... -Genetic Engineering News (press release), Panacos finds oral fusion inhibitors, provides development update ...  Aug 29, 2006
...of their new discovery – three- candidate fusion inhibitors that can be taken orally, unlike their first-in-class companion enfuvirtide (Fuzeon), which must ... -Aidsmap

HIV infection, Prezista, a new protease inhibitor for patients who ...  Aug 26, 2006
Patients in both arms of these trials also used other anti-HIV agents ( nucleoside reverse transcriptase inhibitors ) with or without Enfuvirtide ( Fuzeon ), a ... -Xagena.it

Late winter groundwater levels vary widely  Aug 27, 2006
Enfuvirtide (Fuzeon) is a new type of drug used to treat people with the most advanced stages of HIV/AIDS. Enfuvirtide is the first ... -Scoop.co.nz

Needle-free mode of T-20 dosing looks highly satisfactory for ...  Aug 27, 2006
A needle-free method of administering the anti-HIV drug T-20 (enfuvirtide, Fuzeon) is tolerable and acceptable to patients in the long term, according to a ... -Aidsmap

Investigation of a New Diagnosis of Multidrug-Resistant, Dual ...  Sep 12, 2006
...protease inhibitors. Phenotypic drug-resistance testing indicated that the strain was susceptible to enfuvirtide and efavirenz. The ... -Journal of American Medical Association (subscription)

“Revolutionaryâ€? HIV drug approved in NZ  Aug 27, 2006
The New Zealand AIDS Foundation is welcoming Pharmac’s approval of the “revolutionary� new HIV medication Fuzeon (AKA enfuvirtide or T20). ... -Gay NZ

Draft BHIVA treatment guidelines: respond by Monday September 4 th  Aug 30, 2006
...boosted darunavir (TMC-114, Prezista in the United States where it was approved in June), and suggest that if an individual has never taken enfuvirtide (T-20 ... -Aidsmap

Why did HIV therapy have some benefits for a man with resistance ...  -  12 Dec 2006
Aidsmap,...resistance to all the available antiretroviral drugs except 3TC (lamivudine, Epivir), FTC (emtricitabine, Emtriva) and T-20 (enfuvirtide, Fuzeon).

Long-Term Data Show Tipranavir Continues to Outperform Group of ...  -  Nov 15, 2006
DG News14.4% of patients taking tipranavir/r combined with first-time enfuvirtide use achieved an undetectable viral load of less than 50 copies/mL, P =.0002.1

Pfizer announces expanded access programme for maraviroc  -  Nov 30, 2006
Aidsmap,When it becomes available maraviroc is likely to be the first agent of a new drug class to be approved since enfuvirtide (T-20, Fuzeon), but is likely to be

TMC125 study highlights risk of staying on failing NNRTI regimen  -  Nov 16, 2006
Aidsmap,In this study the background regimen could include a protease inhibitor - usually Kaletra (lopinavir/ritonavir) - and could also include enfuvirtide (Fuzeon

Trimeris Reduces Work Force, Programs To Boost Earnings  -  Nov 15, 2006
BioWorld Online,The viral entry inhibitor Fuzeon (enfuvirtide), partnered with Basel, Switzerland-based F. Hoffmann-La Roche Ltd., sold $33.6 million in North America

Long-Term Data Show Aptivus(R) (tipranavir) Continues to ...  -  Nov 15, 2006
Drug Newswire (press release),...case enfuvirtide: 34.7% vs. 14.4% of patients taking tipranavir/r. achieved a greater mean change from baseline (-2.00 log10 copies/mL vs.



European HIV Drug Resistance Workshop: epidemiology  Apr 20, 2006
...treatment-experienced patients with detectable viral load (ie above 1000 copies) including 12% of patients with exposure to enfuvirtide, “the observed ... - Aidsmap





Physician Attitudes and Beliefs Affect Prescribing Patterns of ...  Apr 5, 2006
...preconceptions and beliefs about injectable drugs appear to explain the unexpectedly low rate of prescriptions for the entry inhibitor enfuvirtide in highly ... - DG News

Efficacy of TMC114/r in Treatment-experienced HIV Patients ...  Apr 4, 2006
...levels less than 10-fold, the response was greatest for those with susceptible nucleoside reverse transcriptase inhibitors (NRTIs) or enfuvirtide (T-20) in the ... - DG News

Pharmacokinetics and Antiretroviral Response Show Promise With ...  Apr 5, 2006
...in a dose of 200 mg. The drugs were combined with at least 2 NRTIs with or without enfuvirtide. Analyses of PK were conducted on ... - DG News

ImQuest Gains Dual-Mechanism HIV Compounds From Samjin  Feb 28, 2006
New York-based Bristol-Myers Squibb Co.’s Sustiva (efavirenz), and by inhibiting viral entry into target cells, a mechanism similar to Fuzeon (enfuvirtide). ... - BioWorld Online (subscription),

CROI: etravirine (TMC125) and darunavir (TMC114) in treatment ...  Feb 13, 2006
...investigators. All participants also received an optimised NRTI background regimen, and some took T-20 (enfuvirtide, Fuzeon). POWER1 ... - Aidsmap,

Positive Pre-Clinical Data on Two New Investigational HIV Fusion ...  Feb 9, 2006
Roche and Trimeris currently market FUZEON(R) (enfuvirtide), the first and only fusion inhibitor available for the treatment of HIV. ... - PR Newswire,

Positive Pre-Clinical Data on Two New Investigational HIV Fusion ...  09 Feb 2006
Roche and Trimeris currently market FUZEON(R) (enfuvirtide), the first and only fusion inhibitor available for the treatment of HIV. ... - PR Newswire

AIDS virus attacked inside & out  Feb 7, 2006
...the infection process. The first fusion inhibitor, enfuvirtide (Fuzeon), is the first injectable antiretroviral drug. The new drugs ... - Monsters and Critics.com

COMUNICADO: Roche & Trimeris Select Two Next Generation HIV Fusion ...  Jan 19, 2006
FUZEON(R) (enfuvirtide), co-developed by Roche and Trimeris (Nasdaq: TRMS) and launched worldwide in 2003, was the first major breakthrough in the treatment of ... - Europa Press

Roche and Trimeris Announce Selection of Two Next Generation HIV ...  Jan 19, 2006
AIDS." First Fusion Inhibitor, FUZEON, continues to provide much needed hope for HIV patients facing treatment failure FUZEON(R) (enfuvirtide), co-developed by ... - APA OTS (Pressemitteilung)

Roche and Trimeris Announce Selection of Two Next Generation HIV ...  Jan 17, 2006
...is a significant milestone which further validates our peptide technology platform." Roche and Trimeris currently market FUZEON(R) (enfuvirtide), the first and ... - PR Newswire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional